| Name | Title | Contact Details |
|---|
SunMedica is a Redding, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
C I Medical is a Norton, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Parter Medical Products, Inc. is a Carson, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Build Your Proactive Myopia Management Practice With Euclid Orthokeratology!Euclid Systems Corporation is a global leader in Advanced Orthokeratology and Proactive Myopia Management. Proven on millions of eyes around the world, Euclid Ortho-K lenses are designed for the individual patient`s eyes. Thanks to the power of Three Factor Fitting, integrating Euclid orthokeratology into your practice is easy! Simply provide three parameters: RX, K Readings, and HVID. This efficient, empirical process yields a category-leading 87%* first fit success. No trial lenses required. With headquarters in, Virginia, USA, Euclid manufactures all products exclusively in the United States with approval from the U.S. Food & Drug Administration (FDA). The company additionally has offices in Shanghai and Beijing, China, and is leading global efforts in myopia management in children.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.